T h e significance of changing the site of injeclion on the absorption and metabolic effects of human growth hormone (GH) was studied. In a cross-over design nine GH-deficient patients were randomized to subcutaneous (s.c.)
G H t r e a t m e n t I n Turner syndrome ( 1 5 ) r e p r e s e n t s a r i s k f a c t o r f o r f u r t h e r r l s e of f r e q u e n t l y ~n c r e a s e d l n s u l l n l e v e l s . Data about t h e r e v e r s r b l l l t y of t h l s phenonienon a r e mlssing. The alm o f o u r s t u d y was t o i n v e s t i g a t e r e v e r s l b l l l t y of changes I n insulin s e c r e t l o " I" TS d u r~n g and a f t e r G H t r e a t m e n t . 9 p r e p u b e r t a l g l r l s , age (meaniSD) 8.721.8 y r , were t r e a t e d wlth GH, I 1U/kg bw/week I n claily s c ~n j e c t -I o n s f o r 12 months. Then t h e t r e a t m e n t was stopped. Glucose t o l e r a n c e and l n s u l l n response were measured by an I W GTT ( 0 . 5 g glucose/kg bw) b e f o r e and a f t e r 3 , 6 , 9 and 12 months of G H t r e a t m e n t and 3 months a f t e r ~t s cessation. Glucose t o l e r a n c e remalned unchanged d u r l n g t h e t r e a t m e n t p e r l o d . FasLlng l n s u l l n l n c r e a s e d from (mean+SD) 13.0+3.8 mIU/I t o 22.9+11.1(9 mo,p:O.02) t o 14.725.0 (12 mo) a n d t o 13.5T8.2 ( 3 mo a f t e r t r e a t m e n t ) . I n t e g r a t e d l n s y l l n s e c r e t l o n (AUC 1 s t phase) was l n c r e a s l n g from 5552154 m I~/ l . m l n -t o 9 monlhs (10242377, pz0.01) and decreased a t 12 months (824+268, pzO.005) and a t 3 months a f t e r therapy (6852184, p=O.01). Peak l n s u l l n response t o t r e a t m e n t was p r e d i c t e d by p r e t r e a t m e n t f a s t i n g l n s v l i n ( r z 0 . 7 4 , pz0.006). In c o n c l u s~o n , p a t i e n t s with TS e x h l b l l an I n c r e a s e i n f a s t l n g and stimulated i n s u l l n s e c r e t l o n d u r i n g t h e f l r s t year of G H t h e r d p y . A d e c r e a s e f o l l o w s by t h e end of t h e f l r s t year and a f t e r therapy.
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Department o f P a e d l a t r l c s , U n i v e r s i t y of Vienna, Austria FlElHODS FOR EVALUATION O F GROWTH IN ULLRICH TURNER SYNDROME (UTS) P a t l e n t s with UTS a r e now ~n c r e a s l n g l y t r e a t e d with Gli t o l mprove growth v e l o c i t y and f l n a l h e l g h t . For e u a l u a t l o n o f t h e e f f e c t i v e n e s s of t h i s t r e a t m e n t different methods lhave been a p p l l e d and we d e m o n s t r a t e t h a t t h e r e s u l l s depend t o some extend on t h e s p e c i f l c method t h a t h a s been used f o r a n a l y s i s . We have revlewed h e i g h t ad growth v e l o c i t y d a t a a s w e l l a s t h e a p p l l e d methodology from 1 3 s t u d l e s on spontaneous growth i n UTS. llost s t u d i e s were based on calculations of annual means o r medlans o f d a t a c o l l e c t e d I n a l o n g i t u d l n a l / c r o s s s e c t i o n a l manner, o t h e r s used mathematical models. Growth velocities were c a l c u l a t e d l o n g~t u d l n a l l y i n ~n d i v ld u a l p a t i e n t s o r were d e r l v e d from h e i g h t c u r v e s g r a p h i c a l l y o r m a t h e m a t i c a l l y . l n d l v l d u a l h e l g h t d a t a f o r a g i v e n age u a r~e d b e tween 2.6 and 7.7 cm when annual means were a p p l l e d and between 0 . 4 and 5 . 8 cm when mathematical models were used. Data on growth veloc i t y were n e a r l y l d e n t l c a l I n a l l studies e x c e p t f o r t h e age of exp e c t e d p u b e r t y , when some a u t h o r s found a mlnor p u b e r t a l growth s p u r t . S t a n d a r d d e v i a t~o n s f o r growth v e l o c l t y l n c r e a s e d a t t h e tlme o f p u b e r t a l age and amounted I n up t o 70L o f Lhe respective growth v e l o c i t y . When v a r i o u s UTS h e~g h t s t a n d a r d s were a p p l l e d f o r e v a l u a t i o n of t r e a t m e n t e f f e c t s we found a difference up t o IOOL o f t h e SD s c o r e <ue t o t h e d i f f e r e n t SD v a l u e s of r e f e r e n c e d a t a . R e s u l t s e x p r e s s e d a s h e i g h t SDS may be b l a s e d by r e l a t i v e l y low mean h e l g h t s of r e f e r e n c e d a t a aL a d o l e s c e n t a g e s . CllO a s a group a r e s h o r t uL b~r l t l i~r~d llavr: r e l a t i v e o v e r w c i~~l~t .
l l~~u I I I ;~~ ~l l d l c a t e tile importance o f Cll f n r prerialal gt.uwlh. I r l n h i g l~ I W Oportion o f p a t l e n t s w l t l~ ~d~o~~a t h~c
CllD ~p e r~n a t a l corr~l,l~cuLlons werc observed. 
i n d i c a t o r s of G I d e f i c i e n c y h a s bfen e v a l u a t r d i n p r e s c h o o l c h i l d r e n o f s h o r t s t a t u r e under t h e a g e of 6 ( n = 7 2 ) , and t h e r e s u l t s canpared w i t h r e s u l t s sfen i n p r e p u b e r t a l c h i l d r e n o f s h o r t s t a t u r e 6 y e a r s o r o l d e r In=65). ?he s u b j e c t s were p l a c e d i n t o 1 o f 3 g r o u p s b a s e d o n QI r e s p o n s e s t o i n s u l i n and a r q i n i n e : n o r m 1 c h i l d r e n o f s h o r t s t a t u r e (NS)
w~t h rrore t h a n lOngJml v a l u e i n o n e o f t h e two t e s t i n g s ; c h~l d r e n w i t h a pat-tlal GI< d e f i c i e n c y IICIID) w i t h less t h a n a 10nqIml i n b t h and nwre than Snqlml i n o n e of two tests; c h i l d r e n w i t h a complete QID IcQID) w i t h less than Snqlrnl i n b o t h tests.
?he QlnP-3 s e n s i t i v i t y f o r d e t e c t i n g cQlD I n p r e s c h o o l c h i l d r e n ( n = 6 ) was 83.3% and its s p e c l f l c l t y f o r NS was 72.7%. Whereas t h e IGF-1 s e n s i t i v i t y was 42.9% ( n = 7 ) . ? h e i r s e n s i t i v i t y f o r d e t e c t i n g W I D was 11 . 8 ( In=17) and 10% ( n = 2 0 ) , r e s p f c t i v e l y . But i n t h e p r e p h r t a l c h i l d r e n , t h e s e n s i t i v i t y o f QIBP-3 and I G -1 f o r pQW was 80.9% ( n = 9 ) and 100% ( n = 9 ) , r e s p c c t l v e l y . The n i n~ o f o u r sLudy was Lo ~nvc:;l.~f:;il.c 1.tio ~~ffccl.:; r,T CII on "cur? t e n s i n c (N'l'l l c v e l s . Plasma sarnpl<:s wcr.c obl.;ibncd I'ros 'I CII-dcCicrer~L c h i l d r e n (I, boy:;. 2 g i r l s ) , a r e ranee 1.1-14.5 yenr:; (11.7:1~1.75 -mcon +SICM) Lo eva1unLc NT and C11 valua::, I,cforc l.r.cnllnrnt. .~nd 17 and 24 -h o u r s a f l e r a subcutaneous rhCH i n j e c t i o n (0.1!, IU/kl:). N' L' concenlrnt i o n s vcrc mcasured by IIIA and cxpreased a:; fmol/ml; C11 v o l u c s wcre e v a l u a l e d by IIIA u s i n g commercial k i L s urrd cxt,rc:::;cd iir, n[:/ml. N'r Icv e l s i n o u r p1.s t,cfor-e CII adrn~nist.mLion (:1.70# 1 .'I2 f m o l / s l ) wcrr :;Ie n i f l c a n L l y lower (p<O.01) t.ll;m Lhosc tn con1 ral:; ( 1'117.5 fmol/l~tl). A ;, ~~n i T i c n n L i n c r e a s e i n N'I va1ut:s werc found 12 11 (.l'J.5'1110.4% Corn01 / m l . ll<O.O1) and 24 1 8 (13.G415.28 f m o l / s~l , p(0.011) ;~fl.cr. CII inJccLlon. Circui.iLinl: CII concenLralions :;i,:nl Ticanl.ty rncrcasod ( p~O . 0 0 5 ) 12 h (7.02L1.23 v:; 12.5Ij+2.18 -nj:/ml), I,uL n o t 74 h nTLcr CII a d m i n~s l~a -Lion (0.'14~0.1'1 nl:/sl).
I t t h u s a p p f a r s t h a t m e n screening
We obscrvcd u clu:;c corrol:ll.ton bcLwecrl N'T and CII v a l u e s boforc LreotmcrrL (p<O.OU!>) .md . i l 1 . 1~~ 241.11 h ;~f l . e r (:I1 inject.ion (p'0.05), buL n o t at. I.hc I2l.h h . ~l r c l l m i n a r y r e s u l t s p o i n t Lo a :;Limul;iLing cTfccL uf' CI1 or) N' 1' , c!:jsc lby ~~#<:ct~;~ntsrn:; sI.1 11 unknonw. 'l'hc Oll-~n~luccd N'I r c l c n s c c o u l d ti, . i u < : 1.0 an Increase i n NB-FA canccnLral. i or):;.
